Contents

Search

drug adverse effects of gliptins

Adverse effects: - nausea [3] - increased risk of pancreatitis [1,5,7,10] & pancreatic cancer [10] - anaphylaxis - severe arthralgias [2] - increased risk for infections [3] - increased risk for hospitalization due to heart failure (3.4% vs 3.0%), NNH = 250 [4] - increased risk of inflammatory bowel disease [8] - increased risk for cholangiocarcinoma [9] - no increased risk of mortality [6] - rarely causes hypoglycemia [11] * unfavorable adverse effect profile including anaphylaxis & pancreatitis [7]

Properties

DRUGS: gliptin FORM: drug adverse effects gliptin

References

  1. Singh S et al Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus. A Population-Based Matched Case-Control Study. JAMA Intern Med. 2013;():1-6. PMID: 23440284 http://archinte.jamanetwork.com/article.aspx?articleid=1656537
  2. FDA MedWatch. August 28, 2015 DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm
  3. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  4. Li L, Li S, Deng K et al Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610 PMID: 26888822 Free Article http://www.bmj.com/content/352/bmj.i610
  5. Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017 Feb; 40:284. PMID: 27659407 http://care.diabetesjournals.org/content/40/2/284 - DeVries JH, Rosenstock J. DPP-4 inhibitor-related pancreatitis: Rare but real! Diabetes Care 2017 Feb; 40:161 PMID: 28108536 http://care.diabetesjournals.org/content/40/2/161
  6. Liu J, Li L, Deng K et al Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499. Review. PMID: 28596247 Free PMC Article
  7. Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
  8. Abrahami D, Douros A, Yin H, et al Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872 PMID: 29563098 http://www.bmj.com/content/360/bmj.k872
  9. Abrahami D, Douros A, Yin H et al Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:k4880 PMID: 30518618 https://www.bmj.com/content/363/bmj.k4880
  10. Lee M et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019 Nov; 42:2057 PMID: 31431452 https://care.diabetesjournals.org/content/42/11/2057
  11. Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019